참고문헌
- Bonanni P, Boccalini S, Bechini A (2009). Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine, 27, 46-53.
- de Villiers EM, Fauquet C, Broker TR, et al (2004). Classification of papillomaviruses. Virology, 324, 17-27. https://doi.org/10.1016/j.virol.2004.03.033
- Ekalaksananan T, Pientong C, Kongyingyoes B, et al (2011). Combined p16INK4a and human papillomavirus testing improves the prediction of cervical intraepithelial neoplasia (CIN II-III) in Thai patients with low-grade cytological abnormalities. Asian Pac J Cancer Prev, 12, 1777-83.
- Eleuterio J Jr, Giraldo PC, Goncalves AK, et al (2007). Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus. Acta Obstet Gynecol Scand, 86, 94-8. https://doi.org/10.1080/00016340601089727
- Hacker NF (2005). Cervical cancer. In 'Practical gynecologic oncology', eds Berek JS. Lippincott Williams & Wilkins, Philadelphia p 337-95.
- Kim J, Kim BK, Lee CH, et al (2012). Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer, 22, 1570-6.
- Lenselink CH, Melchers WJ, Quint WG, et al (2008). Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One, 3, 3743. https://doi.org/10.1371/journal.pone.0003743
- Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
- Nasioutziki M, Daniilidis A, Dinas K, et al (2011). The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer, 21, 79-85. https://doi.org/10.1097/IGC.0b013e3182009eea
- Roelens J, Reuschenbach M, von Knebel Doeberitz M, et al (2012). p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and metaanalysis. Cancer Cytopathol, 120, 294-307. https://doi.org/10.1002/cncy.21205
- Rositch AF, Koshiol J, Hudgens MG, et al (2012). Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer, 133, 1271-85.
- Schmeink C, Massuger L, Lenselink C, et al (2012). Prospective follow-up of 2065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer, 133, 172-81.
- Shen Y, Gong JM, Li YQ, et al (2013). Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China. Clin Chim Acta, 415, 297-301. https://doi.org/10.1016/j.cca.2012.11.005
- Suwiyoga IK (2006). Tes human papillomavirus sebagai skrining alternatif kanker leher rahim. Cermin Dunia Kedokteran, 151, 29-33.
- Vet JN, de Boer MA, van den Akker BE, et al (2008). Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. Br J Cancer, 99, 214-8. https://doi.org/10.1038/sj.bjc.6604417
- von Knebel Doeberitz M (2002). New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer, 38, 2229-42. https://doi.org/10.1016/S0959-8049(02)00462-8
- Wenham RM, Lancaster JM, Berchuck A (2002). Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol, 16, 483-97. https://doi.org/10.1053/beog.2002.0298
- World Health Organization (2006). Comprehensive cervical cancer control: a guide to essential practice. World Health Organization, Geneva, p 16-7, 92-100.